Minireviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4493-4507
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4493
Table 1 The pooled prevalence of celiac disease in various conditions
Condition
Pooled prevalence (%)
95%CI
Definite indications
Chronic diarrhea[18]a3-10NA
Iron deficiency anemia[14]3.22.6-3.9
Short stature[32]
All-cause7.44.7-10.6
Idiopathic11.64.1-22.2
Type 1 diabetes[33]65-6.9
Pediatric age group6.26.1-6.3
Adults2.72.1-2.3
First-degree relatives[37]7.56.3-8.8
Dermatitis herpetiformis[45,46]a9.8-17NA
Down syndrome[47]5.84.7-7.2
Probable indications
Cryptogenic hypertransaminesemia[48]5.93.1-9.34
Autoimmune hepatitis[56]3.51.6-5.3
Irritable bowel syndrome[57]3.32.3-4.5
Diarrhea predominant IBS5.43.3-7.8
Constipation predominant IBS1.80.9-3.0
Mixed-IBS3.11.7-5.1
Osteoporosis[64]1.61.1-2.0
Possible indications
Dyspepsia[65]1.40.9-1.8
Women with infertility[73]
All-cause infertility0.70.2-1.2
Idiopathic infertility0.60.0-1.6
Idiopathic cardiomyopathy[74-78]a0-5.7
Autoimmune thyroid disease[79]1.61.3-1.9
Hypothyroidism1.41-1.9
Hyperthyroidism 2.60.7-4.4
Idiopathic epilepsy[81]2.11.6-2.6
Idiopathic cerebellar ataxia[87]4.33.1-5.9
Dental enamel defects[93,94]1511-21
Table 2 The sensitivity and specificity of the screening tests for celiac disease
Test
Sensitivity
Specificity
Anti-tissue transglutaminase antibody[97]92.8% (95%CI: 90.3-94.8)97.9% (95%CI: 96.4- 98.8)
Anti-endomysial antibody[97]73% (95%CI: 61-83)99.0% (95%CI 98.0-99.0)
Deamidated gliadin peptide antibodies[97]87.8% (95%CI: 85.6-89.9)94.1% (95%CI: 92.5-95.5)
Point-of care tests (107)
Anti-anti-tissue transglutaminase antibody + Anti-gliadin antibody94.0% (95%CI: 89.9-96.5)94.4% (95%CI: 90.9-96.5)
IgA anti-tissue transglutaminase antibody90.5% (95%CI: 82.3-95.1)94.8% (95%CI: 92.5-96.4)